Wang Pengyu, Chen Weiwei, Zhang Jingfeng, Pan Chunshu, Lv Yagui, Sun Yanzi, Wang Yanan, Ma Xuehua, Gao Changyong, Chen Tianxiang, Wu Aiguo, Zheng Jianjun
College of Biological and Environmental Sciences, Zhejiang Wanli University, Ningbo, China.
Department of Radiology, Ningbo No.2 Hospital, Ningbo, China.
Nanomedicine (Lond). 2025 Apr;20(8):869-881. doi: 10.1080/17435889.2025.2480049. Epub 2025 Mar 20.
Atherosclerosis is the leading cause of cardiovascular disease worldwide, posing not only a significant threat to cardiovascular health but also impairing the function of multiple organs, with severe cases potentially being life-threatening. Consequently, the effective treatment of atherosclerosis is of paramount importance in reducing the mortality associated with cardiovascular diseases. With the advancement of nanomedicine and a deeper understanding of the pathological mechanisms underlying atherosclerosis, nanomaterials have emerged as promising platforms for precise diagnosis and targeted therapeutic strategies. These materials offer notable advantages, including targeted drug delivery, enhanced bioavailability, improved drug stability, and controlled release. This review provides an overview of the mechanisms underlying atherosclerotic plaque development and examines nanomaterial-based therapeutic approaches for managing atherosclerotic plaques, including therapies targeting cholesterol metabolism, anti-inflammatory strategies, macrophage clearance, and immunotherapy. Additionally, the paper discusses the current technical challenges associated with the clinical transformation of these therapies. Finally, the potential future integration of nanomaterials, smart nanomaterials, and artificial intelligence in the treatment of atherosclerosis is also explored.
动脉粥样硬化是全球心血管疾病的主要病因,不仅对心血管健康构成重大威胁,还会损害多个器官的功能,严重时可能危及生命。因此,有效治疗动脉粥样硬化对于降低心血管疾病相关死亡率至关重要。随着纳米医学的发展以及对动脉粥样硬化病理机制的深入了解,纳米材料已成为精准诊断和靶向治疗策略的有前景的平台。这些材料具有显著优势,包括靶向药物递送、提高生物利用度、改善药物稳定性和控释。本综述概述了动脉粥样硬化斑块形成的机制,并研究了基于纳米材料的动脉粥样硬化斑块治疗方法,包括针对胆固醇代谢的疗法、抗炎策略、巨噬细胞清除和免疫疗法。此外,本文还讨论了这些疗法临床转化目前面临的技术挑战。最后,还探讨了纳米材料、智能纳米材料和人工智能在未来动脉粥样硬化治疗中的潜在整合。
Nanomedicine (Lond). 2025-4
Cardiovasc Hematol Disord Drug Targets. 2017
Biochim Biophys Acta Mol Basis Dis. 2025-10
Cochrane Database Syst Rev. 2021-4-19
Colloids Surf B Biointerfaces. 2025-6
J Funct Biomater. 2024-12-24
ACS Pharmacol Transl Sci. 2024-12-4
Front Physiol. 2024-11-19
J Diabetes Metab Disord. 2024-8-9
Cell Death Dis. 2024-11-11